ArticleOncogene2011
Activated ROCK II by-passes the requirement of the CDK2 activity for centrosome duplication and amplification.
Article in Oncogene, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.Scientific reports · 2024Article
- Article
- RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling.Nature communications · 2017Article
- The double face of Morgana in tumorigenesis.Oncotarget · 2015Review
- Functional relationship among PLK2, PLK4 and ROCK2 to induce centrosome amplification.Cell cycle (Georgetown, Tex.) · 2015Article
- Centrosomes at M phase act as a scaffold for the accumulation of intracellular ubiquitinated proteins.Cell cycle (Georgetown, Tex.) · 2014Article
- Rho-kinase: regulation, (dys)function, and inhibition.Biological chemistry · 2013Review
- Centrosome dysfunction contributes to chromosome instability, chromoanagenesis, and genome reprograming in cancer.Frontiers in oncology · 2013Review
- RABL6A, a novel RAB-like protein, controls centrosome amplification and chromosome instability in primary fibroblasts.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Initiation of centrosome duplication and DNA replication is coupled, which is primarily achieved by the late G1 phase-specific activation of cyclin-dependent kinase 2 (CDK2)-cyclin E, which triggers both centrosome duplication and DNA replication. Uncoupling of these two events contributes to overduplication of centrosomes, resulting in the presence of more than two centrosomes (centrosome amplification). Centrosome amplification, which is frequently observed in cancers, contributes to tumor development through destabilizing genomes. Nucleophosmin (NPM/B23) is one of the phosphorylation targets of CDK2-cyclin E for the initiation of centrosome duplication. It has been found that NPM/B23 phosphorylated on Thr199 by CDK2-cyclin E acquires a high binding affinity to ROCK II kinase. The Thr199-phosphorylated NPM/B23 physically interacts with and super-activates the centrosomally localized ROCK II, which is a critical event for centrosomes to initiate duplication. Here, we provide direct evidence for the activation of ROCK II as a primary and sufficient downstream event of CDK2-cyclin E for the initiation of centrosome duplication and for the induction of centrosome amplification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.